Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Last trade$95.51
Day change-$5.225 (-5.19%)
Day range$95.00 – $103.35
Volume417,698
Market cap$6.59B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.59B
Price / earnings
—
Price / book
523.97×
Price / sales
—
EV / sales
—
EV / EBITDA
-27.74×
Profitability
Earnings per share
-$3.77
Return on assets
-117.83%
Return on equity
-1,962.77%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.07×
Current ratio
1.7×
Quick ratio
1.7×
Cash ratio
1.62×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$172.81M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KOD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$8.79M
$10.76M
$11.23M
$11.96M
$11.88M
$12.75M
$15.43M
$14.41M
Research and development
$58.3M
$56.08M
$48.55M
$45.49M
$50.48M
$42.76M
$43.64M
$31.77M
Total operating expenses
$67.1M
$66.84M
$59.78M
$57.45M
$62.35M
$55.51M
$59.07M
$46.18M
Operating income
-$67.1M
-$66.84M
-$59.78M
-$57.45M
-$62.35M
-$55.51M
-$59.07M
-$46.18M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$66.22M
-$65.64M
-$58.16M
-$56.74M
-$61.46M
-$54.31M
-$57.46M
-$44.11M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$66.22M
-$65.64M
-$58.16M
-$56.74M
-$61.46M
-$54.31M
-$57.46M
-$44.11M
Net income attributable to common shareholders
-$66.22M
-$65.64M
-$58.16M
-$56.74M
-$61.46M
-$54.31M
-$57.46M
-$44.11M
EBITDA
-$63.01M
-$62.73M
-$55.67M
-$52.91M
-$57.77M
-$50.92M
-$54.47M
-$41.55M
Basic earnings per share
-$1.05
-$1.05
-$0.94
-$1.04
-$1.16
-$1.03
-$1.09
-$0.84
Diluted earnings per share
-$1.05
-$1.05
-$0.94
-$1.04
-$1.16
-$1.03
-$1.09
-$0.84
Recent news
Company coverage with links to the original publishers.
Kodiak Sciences reported a Q3 2026 loss of $1.05 per share, wider than expected, as R&D expenses rose 15.5% year-over-year. However, the company announced positive phase III DAYBREAK study results for lead candidate Zenkuda and KSI-501, both meeting primary endpoints against Regeneron's Eylea. Kodiak plans to submit a BLA for Zenkuda by year-end and expects KSI-101 data in December 2026.
Kodiak Sciences announced positive Phase III DAYBREAK study results for Zenkuda (tarcocimab tedromer), showing non-inferiority to Regeneron's Eylea in treating wet age-related macular degeneration. The drug demonstrated sustained retinal drying with 54% of patients reaching a six-month dosing interval, superior safety profile, and strong durability. Kodiak plans a multi-indication BLA submission in Q4 2026. The stock surged 178% on the announcement.
Four biotech companies—Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics, and Vaxcyte—are approaching significant clinical trial readouts in fall 2026 that could materially impact their valuations. Kodiak will report phase III data for wet AMD treatments, Celldex expects CSU study results, Rapport targets bipolar mania trial outcomes, and Vaxcyte will release pneumococcal vaccine data. These mid- to late-stage readouts represent major catalysts for clinical-stage companies.
A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers therapeutic assessments across various development stages, routes of administration, and molecule types, highlighting emerging opportunities in retinal disease treatment.
The Russell 2000 small-cap index reached an intraday record high on Friday, capping a 13-day rally—its best run since 2020. The surge was driven by President Trump's announcement of a two-week military pause against Iran, which lowered oil prices and boosted expectations for Federal Reserve rate cuts. Regional banks, industrials, and biotech stocks have led the gains, with the iShares Russell 2000 ETF up 8.6% over two weeks compared to the S&P 500's 1.6% gain.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.